دورية أكاديمية
The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancer.
| العنوان: | The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancer. |
|---|---|
| المؤلفون: | Voisin A; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Plaschka M; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.; St. Anna Children´s Cancer Research Institute (CCRI), Vienna, Austria., Perrin-Niquet M; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Twardowski J; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Boutemine I; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Eluard B; Université Paris Cité, NF-κB, Différenciation et Cancer, Paris, France., Lalle G; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Stéphan P; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Bouherrou K; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France., Tonon L; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.; Gilles Thomas Bioinformatics Platform, Fondation Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France., Pommier R; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.; Gilles Thomas Bioinformatics Platform, Fondation Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France., Ferrari A; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.; Gilles Thomas Bioinformatics Platform, Fondation Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France., Klein U; Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Wencker M; Centre International de Recherche en Infectiologie, INSERM U1111, École Normale Supérieure de Lyon, Claude Bernard University Lyon 1, Centre National de la Recherche Scientifique (CNRS), UMR 5308, Lyon, France., Baud V; Université Paris Cité, NF-κB, Différenciation et Cancer, Paris, France., Cassier PA; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.; Medical Oncology, Centre Léon Bérard, Lyon, France., Grinberg-Bleyer Y; Cancer Research Center of Lyon, Labex DEV2CAN, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Centre National de la Recherche Scientifique (CNRS) 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Mar 05; Vol. 15, pp. 1379777. Date of Electronic Publication: 2024 Mar 05 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Neoplasms*/metabolism , Virus Diseases*/metabolism, Animals ; Humans ; Mice ; CD8-Positive T-Lymphocytes/metabolism ; NF-kappa B/metabolism ; NF-kappa B p50 Subunit/metabolism ; Transcription Factor RelA/metabolism |
| مستخلص: | CD8 + T cells are critical mediators of pathogen clearance and anti-tumor immunity. Although signaling pathways leading to the activation of NF-κB transcription factors have crucial functions in the regulation of immune responses, the CD8 + T cell-autonomous roles of the different NF-κB subunits, are still unresolved. Here, we investigated the function of the ubiquitously expressed transcription factor RelA in CD8 + T-cell biology using a novel mouse model and gene-edited human cells. We found that CD8 + T cell-specific ablation of RelA markedly altered the transcriptome of ex vivo stimulated cells, but maintained the proliferative capacity of both mouse and human cells. In contrast, in vivo experiments showed that RelA deficiency did not affect the CD8 + T-cell response to acute viral infection or transplanted tumors. Our data suggest that in CD8 + T cells, RelA is dispensable for their protective activity in pathological contexts. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Voisin, Plaschka, Perrin-Niquet, Twardowski, Boutemine, Eluard, Lalle, Stéphan, Bouherrou, Tonon, Pommier, Ferrari, Klein, Wencker, Baud, Cassier and Grinberg-Bleyer.) |
| References: | Cell Rep. 2014 Sep 11;8(5):1595-606. (PMID: 25159142) Immunity. 2004 Jul;21(1):19-30. (PMID: 15345217) J Virol Methods. 2008 Jan;147(1):167-76. (PMID: 17920702) Cell. 2018 Dec 13;175(7):1958-1971.e15. (PMID: 30449619) Trends Immunol. 2013 Jun;34(6):269-81. (PMID: 23474202) J Biol Chem. 1997 Nov 28;272(48):30412-20. (PMID: 9374532) Br J Cancer. 2021 Jan;124(2):359-367. (PMID: 32929195) J Exp Med. 1997 Mar 3;185(5):953-61. (PMID: 9120401) Nat Commun. 2023 Jan 19;14(1):321. (PMID: 36658158) Immunol Cell Biol. 2017 Mar;95(3):261-271. (PMID: 27649781) Nat Immunol. 2022 Apr;23(4):632-642. (PMID: 35301508) J Immunother Cancer. 2015 Jan 20;3(1):1. (PMID: 25648675) Cell Death Differ. 2005 Nov;12(11):1398-406. (PMID: 15920533) Front Immunol. 2019 Mar 29;10:609. (PMID: 30984185) N Engl J Med. 2013 Dec 26;369(26):2504-14. (PMID: 24369075) Immunity. 2010 Jul 23;33(1):35-47. (PMID: 20643337) Front Immunol. 2018 Jan 22;9:14. (PMID: 29403496) J Immunol Methods. 2016 Mar;430:10-20. (PMID: 26780292) Cell Rep. 2017 Sep 19;20(12):2906-2920. (PMID: 28889989) J Immunol. 2004 Aug 1;173(3):1612-9. (PMID: 15265889) Nat Immunol. 2011 Jul 19;12(8):695-708. (PMID: 21772278) Genome Med. 2016 Mar 17;8(1):28. (PMID: 26988706) Curr Protoc Immunol. 2020 Sep;130(1):e99. (PMID: 32940427) J Exp Med. 2023 Sep 4;220(9):. (PMID: 37273177) Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021) Nature. 1995 Jul 13;376(6536):167-70. (PMID: 7603567) Eur J Immunol. 2020 Jul;50(7):972-985. (PMID: 32012260) J Interferon Cytokine Res. 2011 Jul;31(7):553-9. (PMID: 21631354) J Immunol. 2007 Mar 1;178(5):2932-9. (PMID: 17312138) J Allergy Clin Immunol. 2018 Apr;141(4):1507-1510.e8. (PMID: 29305315) Rheumatology (Oxford). 2022 Dec 23;62(1):347-359. (PMID: 35412596) Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):E1659-E1667. (PMID: 28193872) J Exp Med. 2014 Sep 22;211(10):2103-18. (PMID: 25180063) Int Rev Cell Mol Biol. 2021;361:245-300. (PMID: 34074496) Cell. 2008 Feb 8;132(3):344-62. (PMID: 18267068) J Exp Med. 2005 Apr 4;201(7):1053-9. (PMID: 15809350) Nat Immunol. 2008 Oct;9(10):1140-7. (PMID: 18724371) |
| فهرسة مساهمة: | Keywords: CD8 + T cells; LCMV; NF-KappaB; cancer; immunotherapy |
| المشرفين على المادة: | 0 (NF-kappa B) 0 (NF-kappa B p50 Subunit) 0 (Transcription Factor RelA) 0 (RELA protein, human) 0 (Rela protein, mouse) |
| تواريخ الأحداث: | Date Created: 20240320 Date Completed: 20240321 Latest Revision: 20240416 |
| رمز التحديث: | 20240417 |
| مُعرف محوري في PubMed: | PMC10948531 |
| DOI: | 10.3389/fimmu.2024.1379777 |
| PMID: | 38504985 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1379777 |